Xgeva® (denosumab): Risk of Multiple Vertebral Fractures (MVF) Following Treatment Discontinuation

User Rating: 3 / 5

Star ActiveStar ActiveStar ActiveStar InactiveStar Inactive

Date: 8 September 2017



Cases of multiple vertebral fractures (MVF) have occurred rarely following discontinuation of Xgeva® in patients participating in ongoing clinical trials, particularly patients with risk factors such as osteoporosis or prior fracture. The fractures were not due to bone metastases. Healthcare professionals are advised to counsel patients not to interrupt Xgeva® therapy without their physician’s advice. When Xgeva® treatment is discontinued, healthcare professionals should also evaluate the individual patient’s risk for vertebral fractures.

A Direct Healthcare Professional Communication (DHPC) has been issued by Zuellig Pharma Sdn. Bhd. in agreement with NPRA to highlight this safety issue. Please refer to this DHPC for further information.


National Pharmaceutical Regulatory Agency (NPRA)
Lot 36, Jalan Universiti, 46200 Petaling Jaya, Selangor, Malaysia.
  • Email: npra@npra.gov.my
  • Phone: +603-7883 5400
  • Fax: +603-7956 2924, +603-7956 7075


The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Mobile Web :

Site Last Modified

  • Last Modified: Monday 19 October 2020, 21:47:07.
© Copyright 2019 . All Rights Reserved National Pharmaceutical Regulatory Agency NPRA

Main Menu English

Choose Your Language